Single Technology Appraisals (STAs)

SCHARR-TAG has produced technology assessment reports since 2000. We are a dedicated team including experienced economic modellers, systematic reviewers, statisticians, information specialists and project managers.

Off

2024

Blinatumomab with chemotherapy for consolidation treatment of Philadelphia-chromosome-negative CD19-positive B-precursor acute lymphoblastic leukaemia with no measurable residual disease [ID6405].

Breast cancer (BRCA positive, HER2 negative, metastatic) - olaparib (after chemotherapy)(Review of TA762) [ID6336].

Sodium thiosulfate for preventing ototoxicity in people aged 1 month to 17 years with localised cancer having cisplatin chemotherapy [ID1001].

Sparsentan for treating primary IgA nephropathy [ID6308].

Fedratinib for treating disease-related splenomegaly or symptoms in myelofibrosis (Review of TA756) [ID5115].

Sipavibart for preventing COVID-19 Evusheld 2.0 [ID6282].

Lung cancer (non-small cell, EGFR positive) - osimertinib (adjuvant) [Review of TA761] [ID5120].

Isatuximab with pomalidomide and dexamethasone for treating relapsed and refractory multiple myeloma [ID4067].

Glioma (BRAF V600E, aged 1-17) - dabrafenib (with trametinib) [ID5104].

Tisagenlecleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people aged 25 and under (MA review of TA554) [ID6290].

Abaloparatide for treating osteoporosis in postmenopausal women [ID882].

2023

Trastuzumab deruxtecan for treating HER2-Low metastatic or unresectable breast cancer after chemotherapy [ID3935].

Ritlecitinib for treating moderate to severe alopecia areata in people 12 years and over [ID4007].

Tixagevimab–cilgavimab for preventing COVID-19 Evusheld [ID6136].

Cabozantinib for previously treated differentiated thyroid cancer after radioactive iodine [ID4046].

Eptinezumab for preventing migraine [ID3803].

Pembrolizumab with trastuzumab and chemotherapy for untreated HER2- positive advanced gastric or gastro-oesophageal junction cancer [ID3742].

2022

Ripretinib, after 3 therapies, for advanced gastrointestinal stromal tumours [ID3805].

177Lu-PSMA-617 for treating PSMA-positive hormone-relapsed metastatic prostate cancer after 2 or more therapies [ID3840].

Slow-release potassium bicarbonate and potassium citrate for treating distal renal tubular acidosis [ID3787].

KTE-X19 Autologous auto-CD19-transduced CD3+ cells for treating relapsed or refractory B-precursor acute lymphoblastic leukaemia in adults [ID1494].

Duvelisib for treating relapsed or refractory chronic lymphocytic leukaemia [ID1083].

Nivolumab for treating resected high-risk invasive urothelial cancer [ID2694].

Alpelisib with fulvestrant for HR positive, HER2 negative, PIK3CA positive breast cancer (review of TA652) [ID3929].

Pembrolizumab in combination for untreated, locally advanced or metastatic, triple negative breast cancer [ID1546].

2021

Dapagliflozin for treating chronic kidney disease [ID3866].

Adjuvant nivolumab for oesophageal cancer [ID1676].

Osimertinib for adjuvant treatment of EGFR mutation-positive non-small-cell lung cancer after complete tumour resection [ID3835].

Risdiplam for treating spinal muscular atrophy in children and adults [ID1631].

Fedratinib for splenomegaly and symptoms in myelofibrosis [ID1501].

Ibrutinib for Waldenstrom's [ID3778].

Pembrolizumab for advanced/unresectable or metastatic urothelial cancer [ID1634].

Pembrolizumab with carboplatin and paclitaxel or nab-paclitaxel for untreated metastatic squamous non-small-cell lung cancer [ID1683].

2020

Isatuximab with pomalidomide and dexamethasone for treating relapsed or refractory multiple myeloma [ID1477].

Tafamidis for treating transthyretin amyloid cardiomyopathy [ID1531].

Gilteritinib for treating relapsed or refractory acute myeloid leukaemia [ID1484].

Crisaborole for treating mild to moderate atopic dermatitis in people aged 2 years and older [ID1195].

Trifluridine–tipiracil for treating metastatic gastric or gastro-oesophageal junction cancer after 2 or more therapies [ID1507].

Obinutuzumab with bendamustine for treating follicular lymphoma refractory to rituximab [ID1583].

Acalabrutinib for treating chronic lymphocytic leukaemia [ID1613].

Alpelisib in combination with fulvestrant for treating advanced hormone-receptor positive, HER2-negative, PIK3CA-positive breast cancer [ID1412].

Atezolizumab in combination with bevacizumab for hepatocellular carcinoma [ID1655].

2019

Clostridium botulinum neurotoxin type A for treating hypersalivation associated with neurological conditions [ID1150].

Pentosan polysulfate sodium for treating bladder pain syndrome [ID1364].

Olaparib for maintenance treatment of BRCA-mutated ovarian, fallopian tube and peritoneal cancer after response to initial platinum-based chemotherapy [ID1124].

Pembrolizumab with carboplatin and paclitaxel for untreated squamous non-small-cell lung cancer [ID1306].

Blinatumomab for treating B-precursor, minimal residual remission acute lymphoblastic leukaemia [ID1036].

Sodium zirconium cyclosilicate for treating hyperkalaemia [ID1293].

Trastuzumab emtansine for locally adcanced or metastatic HER2 positive breast cancer after trastuzumab & a taxane (review of TA371) [ID1013].

2018

Nusinersen for treating infant or child spinal muscular atrophy [ID1069].

Regorafenib after sorafenib, for treating unresectable hepatocellular carcinoma [ID991].

Sarilumab after TNFnhibitors for treating active rheumatoid arthritis [ID994].

Cx601 for treating complex perianal fistula in non-active or mildly-active luminal Crohn’s disease [ID960].

2017

Baricitinib for treating moderate to severe rheumatoid arthritis [ID979].

Ponatinib for treating chronic myeloid leukaemia [ID671].

Tofacitinib for the treatment of moderate to severe active rheumatoid arthritis after failure of disease-modifying anti-rheumatic drugs [ID526].

2016

Ibrutinib for treating Waldenstrom’s macroglobulinaemia [ID884].

Ibrutinib for treating relapsed or refractory mantle cell lymphoma [ID753].

Obinutuzumab in combination with bendamustine for treating rituximab-refractory follicular lymphoma [ID841].

Pertuzumab for treating early, HER 2 positive breast cancer [ID767].

Certolizumab pegol for treating rheumatoid arthritis following inadequate response to a TNF inhibitor [ID824].

Idiopathic pulmonary fibrosis - pirfenidone [ID837].

Adalimumab for treating moderate to severe hidradenitis suppurativa [ID812].

Cabazitaxel for the second-line treatment of hormone-refractory, metastatic prostate cancer [ID889].

Olaparib for the maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer with BRCA 1 or 2 mutations following response to prior platinum-based chemotherapy [ID735].

Hypercholesterolaemia (primary), dyslipidaemia (mixed) - evolocumab [ID765].

Vedolizumab for treating moderate to severe active Crohn’s disease after prior therapy [ID690].

Vedolizumab for ulcerative colitis [ID691].

Degarelix for the treatment of advanced hormone-dependent prostate cancer [ID590].

Sofosbuvir-ledipasvir for treating genotype 1 chronic hepatitis C [ID742].

Sipuleucel-T for the treatment of metastatic castrate-resistant prostate cancer [ID573].

2015

Mepolizumab for treating severe eosinophilic asthma [ID798].

2014

Trastuzumab emtansine for the treatment of locally advanced or metastatic HER2 - positive breast cancer after treatment with trastuzumab and a taxane [ID603].

Nalmefene for reduction of alcohol consumption in alcohol-dependent patients [ID660].

Rivaroxaban for the prevention of adverse outcomes in patients after the acute management of acute coronary syndrome [ID532].

2013

Rituximab in combination with corticosteroids for treating anti-neutrophil cytoplasmic antibody-associated vasculitis [ID567].

Aripiprazole for the treatment and prevention of acute manic and mixed episodes in bipolar disorder in children and adolescents [ID305].

2012

Pegloticase for the treatment of hyperuricaemia in people with symptomatic gout whose disease is refractory to conventional urate-lowering therapy, or in whom conventional urate-lowering therapy is contraindicated or not tolerated [ID521].

Alteplase for treating acute ischaemic stroke (review of technology appraisal guidance 122) [ID536].

Rivaroxaban for the treatment of deep vein thrombosis and secondary prevention of venous thromboembolism [ID437].

Bivalirudin for the treatment of ST-segment elevation myocardial infarction (10/09/01).

Abatacept for the treatment of rheumatoid arthritis after the failure of conventional disease-modifying anti-rheumatic drugs (10/24/01).

Golimumab for the treatment of rheumatoid arthritis after failure of previous disease-modifying antirheumatic drugs (08/118/01).

Mifamurtide for the treatment of osteosarcoma (08/77/01).

2011

Cabazitaxel for the second-line treatment of hormone-refractory, metastatic prostate cancer (10/49/01).

Trabectedin for the treatment of relapsed ovarian cancer (08/212/01).

2010

Bevacizumab in combination with oxaliplatin and either 5FU or capecitabine for the treatment of metastatic colorectal cancer (08/211/01).

Trabectedin for the treatment of advanced metastatic soft tissue sarcoma (08/92/01).

2009

Rivaroxaban for the prevention of venous thromboembolism after total hip or total knee replacement in adults (08/03/01).

Febuxostat for the management of hyperuricaemia in people with gout (07/69/01).

Dabigatran etexilate for the prevention of venous thromboembolism after hip or knee replacement surgery in adults (07/90/01).

Varenicline for smoking cessation (06/50/01).

Alteplase for the treatment of acute ischaemic stroke (06/51/01).

Docetaxel for the adjuvant treatment of early node-positive breast cancer: a single technology appraisal (05/53/01).

Trastuzumab for the treatment of primary breast cancer in HER2-positive women: a single technology appraisal (05/51/01).